Thu Jan 27, 2011 5:46pm EST
* BSI-201 misses main goals of Phase III study
* Survival benefit seen in second- and third-line patients * Did not significantly add to toxicity NEW YORK, Jan 27 (Reuters) - An experimental drug for a
type of advanced breast cancer being developed by
Sanofi-Aventis (SASY.PA) failed to extend life or slow disease
progression in a late-stage clinical trial, the French
drugmaker said on Thursday. The news was particularly
No comments:
Post a Comment